Treatment of Peritoneal Surface Malignancies, An Issue of Surgical Oncology Clinics, 1st Edition

Author :
By Jesus Esquivel, MD, FACS
This issue of the Surgical Oncology Clinics of North America, Guest Edited by Dr. Jesus Esquivel, will focus on the current status and future directions of the treatment of the most common peritoneal surface malignancies: appendix cancer, colorectal ...view more
This issue of the Surgical Oncology Clinics of North America, Guest Edited by Dr. Jesus Esquivel, will focus on the current status and future directions of the treatment of the most common peritoneal surface malignancies: appendix cancer, colorectal cancer, ovarian cancer, gastric cancer, and peritoneal mesothelioma. This issue will also outline some of the most common issues that arise regarding cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), such as pharmacokinetic rationale of heat and intraperitoneal chemotherapy, HIPEC techniques and safety considerations, how to start a peritoneal surface malignancy program, anesthesia considerations during cytoreductive surgery and HIPEC, patient selection for cytoreductive surgery and HIPEC, and the role of dystemic chemotherapy in the management of peritoneal surface malignancies of appendiceal and colorectal origin.
ISBN :
9781455754243
Publication Date :
05-10-2012
Add to Cart
This issue of the Surgical Oncology Clinics of North America, Guest Edited by Dr. Jesus Esquivel, will focus on the current status and future directions of the treatment of the most common peritoneal surface malignancies: appendix cancer, colorectal cancer, ovarian cancer, gastric cancer, and peritoneal mesothelioma. This issue will also outline some of the most common issues that arise regarding cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC), such as pharmacokinetic rationale of heat and intraperitoneal chemotherapy, HIPEC techniques and safety considerations, how to start a peritoneal surface malignancy program, anesthesia considerations during cytoreductive surgery and HIPEC, patient selection for cytoreductive surgery and HIPEC, and the role of dystemic chemotherapy in the management of peritoneal surface malignancies of appendiceal and colorectal origin.

Author Information
By Jesus Esquivel, MD, FACS, Director, Peritoneal Surface Malignancy Program, St. Agnes Hospital